U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07763639) titled 'A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors' on Aug. 10.
Brief Summary: This is an open-label, multicenter, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of SI-B036 Bispecific Antibody Injection in patients with locally advanced or metastatic head and neck tumors and other solid tumors.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Head and Neck Tumors
Solid Tumors
Intervention:
DRUG: SI-B036
Administration by intravenous infusion for a cycle of 3 weeks....